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Value in Health has recently devoted a special issue to the
quality-adjusted life years (QALY) (Volume 12, Issue s2), essen-
tially depicting it as the only realistic alternative to value health
outcomes. Although some of the QALYs’ shortcomings were
described, the focus of the special issue was on “building a
pragmatic road,” developing avenues to possible solutions for
the problems at hand.
In the current issue, Joore et al. raise yet another, potentially
serious ﬂaw for the application of QALYs in cost-utility analysis
[1]. The authors used ﬁve dataset of mostly piggy-back economic
analyses, where both the widely used health state surveys EQ-5D
and SF-6D (a SF-36 derivate) health utility state surveys had been
conducted, to compute cost-effectiveness acceptability curves via
probabilistic sensitivity analysis. The main ﬁnding of their
elegant study is that the small differences in utilities that were
derived from the two different surveys might result in substan-
tially different results when applied in cost-utility analysis. This
potentially changes the interpretation of the results of cost-utility
analyses which has implications for the decision-makers.
Although a Medline search reveals around 80 articles which
both mention EQ-5D and SF-6D, the earliest one dating back to
2001, the differences in EQ-5D- or SF-6D-derived utilities are at
present still unclear. Ceiling and ﬂoor effects as well as different
sensitivities in milder health states have been described a while
ago; it was also shown that different scoring in the survey instru-
ment with economic valuation methods such as time trade-off,
standard gamble, or visual analog scale might produce
signiﬁcantly different utilities. Nevertheless, the impact on incre-
mental QALYs and incremental cost-utility ratios is still unclear.
The present study adds that SF-6D-derived utilities, despite being
scored by a time trade-off-valuated algorithm, are not always
higher and might not always have narrower ranges. The EQ-5D,
on the other hand, might not always be less sensitive in milder
health states. Finally, the choice of the instrument can in some
cases ﬂip the decision, from inferior to cost-effective, or from
dominant to not cost-effective.
The authors conclude that “a systematic difference in the
probability of accepting the cost-utility of interventions as a result
of the choice of utility instrument would seriously bias the com-
parability of the results of economic evaluations.” Nevertheless,
not only systematic but also occasional differences could seriously
damage the reputation of the QALY as a universal “currency” of
health beneﬁts across conditions and intervention strategies.
There are three implications from this study. First, there needs
to be more research on the consequences of using either EQ-5D
or SF-6D. If the ﬁve studies chosen by Joore et al., and this is
likely, are not the only ones affected by the choice of the survey
instrument, we need guidance from ISPOR for practice. Second,
EQ-5D- and SF-6D-derived utilities are valuated by two different
methods, time trade-off and standard gamble, which are consid-
ered the gold standard from an economics perspective. The
decision-analytic community should consider standardizing on
either one instrument or a common rescaling on both instru-
ments. Third, the results from Joore et al. point at a potential for
misuse. Several of their cost-effectiveness acceptability curves
slope upward or downward depending on the survey instrument
used. Manufacturers submitting decision-analytic models for
appraisal processes to, for example, the U.K.’s National Institute
for Clinical Excellence could “cherry-pick” the more favorable
result. Moreover, the existence of the other, less favorable utility
dataset could be obscured as in recent controversies around
clinical efﬁcacy datasets. ISPOR should consider recommending
mandatory prospective registration of health state assessments,
similarly to the U.S. Food and Drug Administration’s Clinical-
Trials.gov or the Cochrane Central Register of Controlled Trials.
Economic piggy-back analyses could even be registered in these
databases. It is up to us to act upon these alarming ﬁndings, and
preserve the credibility of the QALY.
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